XENPOZYME Sanofi-Aventis Australia Pty Ltd
Product name
XENPOZYME
Sponsor
Accepted date
Oct-2022
Active ingredients
olipudase alfa
Proposed indication
For the treatment of non-central
nervous system (CNS) manifestations of acid sphingomyelinase deficiency (ASMD).
nervous system (CNS) manifestations of acid sphingomyelinase deficiency (ASMD).
Application type
A (new medicine)
Publication date
Oct-22
Registration process
Orphan drug
Sponsors receive a fee waiver to help bring medicines for a small population to market.